Calcium 2-aminoethylphosphate - History, Treatments, Uses, and Risks

History, Treatments, Uses, and Risks

CA-AEP was discovered by Erwin Chargaff, best known for his work that eventually led to the discovery of the double helix structure of DNA, in 1941. His findings were largely ignored for the first two decades but studies over the last 30 years have shown that Ca-AEP plays a vital role in maintaining cell membrane integrity and improving cellular functions. People have been using this to treat a host of ailments including multiple sclerosis, diabetes, asthma and immune disorders.

The first trial applications of Ca-AEP were for the treatment of multiple sclerosis (MS). In 1967 the German Health Authority approved the use of Ca-AEP for MS. MS, an inflammatory demyelinating condition, is one of the most common diseases of the central nervous system (brain and spinal cord). Myelin, the fatty material that surrounds nerves, acts as an insulator, much like the covering of an electric wire. An analysis of more than 2,000 patients who were treated with colamine salts in Germany over the course of 24 years revealed greater efficacy from Ca-AEP treatments than other known treatments. In 1986, Dr. George Morrissette conducted a retrospective poll of patients in the USA who originally had begun Ca-AEP treatment in Germany for MS. 82% of the almost 300 patients that entered the study showed a positive benefit from Ca-AEP therapy. And when treatment began in the early stages of MS, positive results rose to 92%.

After 30 years of Ca-AEP and calcium orotate therapies with over 3,500 patients with multiple sclerosis, the risk of bone fractures was drastically reduced. Furthermore, surgeons in six surgical centers located in USA and Europe reported finding extremely solid bone when implanting new joints in patients who were taking Ca-AEP combined with calcium and magnesium orotate for at least four years prior to their surgeries.

In 1967, the German Health Authority approved calcium 2-AEP as an official treatment for multiple sclerosis. In fact, 2-AEP is the only natural official MS treatment reimbursed by the German equivalent of the US Social Security System.

The U.S. National Multiple Sclerosis Society states that “calcium EAP protocol is not recommended by the Medical Advisory Board of the National MS Society.” The National MS Society warns of side effects and risk, but they do not list any on their website for this treatment. They do state that it “may include a powerful drug that suppresses the immune system” but they do not mention what this drug is.

Calcium 2-AEP is actually manufactured by numerous nutraceutical companies and is sold online and in health food stores.